CoChat

The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index; 346 of the 558 sources its claims cite were checked for support.

Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges

Open access
Lunca, Sorinel, Morarasu, Stefan, Dimofte, Gabriel Mihail · 2026 · International Journal of Molecular Sciences

Abstract

Radiotherapy is a cornerstone of breast cancer treatment, but its efficacy is frequently limited by intrinsic and acquired radioresistance as well as dose-limiting toxicity to surrounding normal tissues. Nanoparticle-mediated radiosensitization has emerged as a promising strategy to enhance the therapeutic index of irradiation by combining physical dose amplification with biological, microenvironmental, and immunological modulation. In this systematic review, we evaluated preclinical evidence on nanoparticle-mediated radiosensitization in breast cancer, with emphasis on nanoplatform design, mechanistic patterns, therapeutic efficacy, and translational relevance. A total of 66 studies published between 2015 and 2026 were included. The identified systems encompassed a broad range of materials, including gold-, silver-, platinum-, bismuth-, gadolinium-, polymer-, lipid-, and hybrid-based nanoplatforms, frequently incorporating targeting ligands, catalytic components, biomimetic coatings, or therapeutic payloads. Enhanced radiation responses were most commonly associated with high-atomic-number (high-Z)-mediated energy deposition, increased reactive oxygen species generation, and enhanced DNA damage persistence. Additional mechanisms, including redox modulation, hypoxia targeting, regulated cell death, and immune activation, reflect the evolution of nanoparticle-assisted radiotherapy from predominantly physical radioenhancement toward multifunctional physicobiological strategies. Triple-negative breast cancer models predominated throughout the literature. Across preclinical models, nanoparticle-assisted irradiation consistently improved clonogenic survival, tumor control, and, in selected studies, survival. However, substantial heterogeneity in study design and limited use of rigorous radiobiological endpoints restricted cross-study comparability. The available preclinical evidence indicates that the most promising nanoparticle-mediated radiosensitization strategies integrate physical dose enhancement with biologically active mechanisms targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling, and tumor microenvironmental resistance. Collectively, these findings suggest that the field is evolving from predominantly physical radioenhancement toward multifunctional, mechanism-driven physicobiological strategies. However, clinical translation remains constrained by methodological heterogeneity and limited radiobiological validation, highlighting the need for standardized preclinical evaluation and clinically feasible nanoplatforms tailored to subtype-specific mechanisms of radioresistance.

Overview

CoChat Summary

TL;DR

This systematic review synthesizes 66 preclinical studies (2015–2026) on nanoparticle-mediated radiosensitization in breast cancer, finding that enhanced radiation responses are most often linked to high-Z dose amplification, ROS generation, and DNA damage. Multifunctional nanoplatforms show broader therapeutic effects, but clinical translation is constrained by methodological heterogeneity and limited formal radiobiological validation.

Key findings

  • Among 66 included studies, triple-negative breast cancer was the predominant model (39/66, 59%), followed by HER2-positive (4/66, 6%), luminal (1/66, 2%), mixed/multiple subtypes (6/66, 9%), and general/unspecified models (16/66, 24%); 44/66 (67%) combined in vitro and in vivo work, 16/66 (24%) were in vitro only, and 6/66 (9%) were in vivo only.
  • Mechanistic endpoints were dominated by ROS generation (63/66, 95.5%) and enhanced DNA damage (50/66, 75.8%); regulated cell death was investigated in 32/66 (48.5%), most commonly apoptosis (23/66, 34.8%), while ferroptosis (5/66, 7.6%), immunogenic cell death (3/66, 4.5%), and pyroptosis (2/66, 3.0%) were less frequent; hypoxia modulation and immune activation were reported in 10/66 (15.2%) and 11/66 (16.7%), respectively.
  • Formal radiobiological validation was limited: clonogenic survival assays were reported in 26/66 studies (39% or 39.4%), SER/DEF metrics in only 5/66 (8% or 7.6%), survival outcomes in 5/66 (8%), toxicity/safety assessments in 22/66 (33%), and comprehensive radiotherapy protocol reporting in only 8/66 (12%).
  • Representative outcomes included CXCR4-targeted gold nanoparticles with a DEF10 of 1.20, Au–Pt bimetallic nanoparticles reducing 4T1 tumor volume from 459.5 ± 76.09 mm³ after irradiation alone to 231.7 ± 63.35 mm³ with combined treatment, HfO2@MnO2–GOx inhibiting primary tumor growth by approximately 67% and distant tumor growth by up to 98.7%, and Au@AgBiS2-PEG leaving approximately 50% of treated animals alive at 60 days versus complete control mortality within 14–43 days.

Methods

  • PRISMA-guided systematic review prospectively registered in PROSPERO (CRD420261365298); MEDLINE/PubMed and EMBASE were searched from 1 January 2015 to 2 March 2026 for English-language preclinical original studies on nanoparticle-based radiosensitization in breast cancer with irradiation.
  • From 1,905 records, 393 duplicates were removed, 1,512 records were title/abstract screened, 199 full texts were assessed, and 66 studies met inclusion criteria; data were extracted using a predefined framework, and study quality was assessed across six domains.
  • Because of heterogeneity in nanoplatforms, models, irradiation protocols, and outcomes, no formal meta-analysis was performed; data were synthesized qualitatively, with radiosensitization distinguished from radioenhancement based on validated endpoints such as clonogenic survival, SER, DEF, or DMF.

Limitations

  • The paper states substantial heterogeneity in nanoparticle composition, functionalization, experimental models, radiotherapy protocols, and outcome assessment; radiotherapy reporting was frequently incomplete, especially dose rate, fractionation, beam energy, and treatment timing, and only 8/66 studies (12%) provided comprehensive radiation details.
  • The paper states that mechanistic interpretation was often based on associative biomarkers rather than pathway-specific inhibition or rescue experiments, and that formal radiosensitization was inconsistently demonstrated because clonogenic assays and SER/DEF metrics were used in only 26/66 (39%) and 5/66 (8%) studies, respectively.
  • The paper also states that TNBC models predominated while HER2-positive and luminal subtypes were underrepresented, that complex integrated nanoplatforms raise concerns about reproducibility, scalability, biodistribution, long-term toxicity, immunogenicity, and regulatory approval, and that publication bias toward positive findings may overestimate benefit; evident from the text, the qualitative design and lack of meta-analysis preclude quantitative cross-platform comparison.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms27146522

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA 2020 flow diagram illustrating the process of study identification, screening, eligibility assessment, and inclusion.
Figure 1 PRISMA 2020 flow diagram illustrating the process of study identification, screening, eligibility assessment, and inclusion.CC BY · PubMed Central
Figure 2 Quantitative overview of the included studies and radiobiological validation endpoints. (A) Distribution of breast cancer molecular subtypes represented in the 66 included studies. (B) Distribution of experimental designs according to the use of in vitro, in vivo, or combined in vitro/in vivo models. (C) Frequency of key radiobiological validation endpoints, including clonogenic survival assays, formal radiosensitization metrics (sensitizer enhancement ratio [SER] or dose enhancement factor [DEF]), and survival assessment. The figure highlights the predominance of triple-negative breast cancer (TNBC) models, the widespread use of combined experimental designs, and the limited use of gold-standard radiobiological validation endpoints across the included literature.
Figure 2 Quantitative overview of the included studies and radiobiological validation endpoints. (A) Distribution of breast cancer molecular subtypes represented in the 66 included studies. (B) Distribution of experimental designs according to the use of in vitro, in vivo, or combined in vitro/in vivo models. (C) Frequency of key radiobiological validation endpoints, including clonogenic survival assays, formal radiosensitization metrics (sensitizer enhancement ratio [SER] or dose enhancement factor [DEF]), and survival assessment. The figure highlights the predominance of triple-negative breast cancer (TNBC) models, the widespread use of combined experimental designs, and the limited use of gold-standard radiobiological validation endpoints across the included literature.CC BY · PubMed Central
Figure 3 Mechanism-driven multifunctional nanoplatforms for radiosensitization in breast cancer. This figure illustrates how nanoparticle-assisted radiotherapy enhances tumor response through the rational integration of complementary physical, chemical, biological, and immunological mechanisms. Functional radiosensitizing components, including high-atomic-number materials, catalytic/ROS-generating components, and biologically active agents, provide physical dose amplification and/or biological modulation of radiosensitivity. In contrast, delivery and targeting platforms, including polymeric, lipid, and biomimetic nanoparticles, do not necessarily act as radiosensitizers by themselves but facilitate tumor delivery, cellular uptake, targeting, and integration of functional components. Integrated multifunctional nanoplatforms may enhance radiotherapy through high-Z dose amplification, ROS generation, persistent DNA damage, hypoxia and redox modulation, regulated cell death, immune activation, and microenvironmental remodeling. These coordinated mechanisms can lead to reduced clonogenic survival, tumor growth inhibition, improved survival in preclinical models, potential systemic antitumor effects, and an improved therapeutic index. Upward and downward arrows indicate an increase and decrease, respectively, in the level, activity, or biological effect of the corresponding molecule or outcome. Image generated via Canva Pty Ltd., Sydney, Australia (https://www.canva.com/magic-design/, accessed on 7 July 2026).
Figure 3 Mechanism-driven multifunctional nanoplatforms for radiosensitization in breast cancer. This figure illustrates how nanoparticle-assisted radiotherapy enhances tumor response through the rational integration of complementary physical, chemical, biological, and immunological mechanisms. Functional radiosensitizing components, including high-atomic-number materials, catalytic/ROS-generating components, and biologically active agents, provide physical dose amplification and/or biological modulation of radiosensitivity. In contrast, delivery and targeting platforms, including polymeric, lipid, and biomimetic nanoparticles, do not necessarily act as radiosensitizers by themselves but facilitate tumor delivery, cellular uptake, targeting, and integration of functional components. Integrated multifunctional nanoplatforms may enhance radiotherapy through high-Z dose amplification, ROS generation, persistent DNA damage, hypoxia and redox modulation, regulated cell death, immune activation, and microenvironmental remodeling. These coordinated mechanisms can lead to reduced clonogenic survival, tumor growth inhibition, improved survival in preclinical models, potential systemic antitumor effects, and an improved therapeutic index. Upward and downward arrows indicate an increase and decrease, respectively, in the level, activity, or biological effect of the corresponding molecule or outcome. Image generated via Canva Pty Ltd., Sydney, Australia (https://www.canva.com/magic-design/, accessed on 7 July 2026).CC BY · PubMed Central

Verification

Claims the paper makes

107 Valid · 7 Not valid · 14 Not checked · 130 Own results and interpretations

177 more claims · 67 with their cited sources checked

Create a free account to see all 258 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 69
  • Probably not a substantial claim. 11
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 114 references

Research works printed but not linked: 1

  1. Bray, 2024, Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide, CA Cancer J. Clin., 74, 229

Metadata

Authors
Lunca, S., Morarasu, S., & Dimofte, G. M.
Affiliations
  • Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
  • Grigore T. Popa University of Medicine and Pharmacy (RO)
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-07-22
Volume
27
Issue
14
Pages
6522
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7170042542
Cited by
2
References
114
Citations by year
2026: 2
FWCI
2.57
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
Grigore T. Popa University of Medicine and Pharmacy (326475)
Topics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
Keywords
breast cancer, radioresistance (biology), gold nanoparticles, platinum nanoparticles, bismuth nanoparticles, gadolinium nanoparticles, reactive oxygen species, redox modulation, tumor microenvironment, triple-negative breast cancer, immune activation, translational challenges
MeSH terms
Animals, Breast Neoplasms, Female, Humans, Radiation Tolerance, Radiation-Sensitizing Agents, Nanoparticles, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges. https://app.cochat.ai/papers/10.3390/ijms27146522
The paper
Lunca, S., Morarasu, S., & Dimofte, G. M. (2026). Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27146522

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.